Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Metastatic Pancreatic Cancer Market to Proliferate Immensly, Predicts DelveInsight | Key Companies to Look Out for - FibroGen, AstraZeneca, Jiangsu HengRui, ImmunityBio, SynerGene, Mirati, Incyte, Astellas, AbbVie, Cue Biopharma, PureTech

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

15 Jun, 2023, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

The dynamics of the metastatic pancreatic cancer market are anticipated to change in the coming years owing to the rising healthcare spending across the globe and the expected launch of novel and emerging therapies by key companies such as FibroGen, SynCore Biotechnology, AstraZeneca, Ab Science, and others.

LAS VEGAS, June 15, 2023 /PRNewswire/ -- DelveInsight's Metastatic Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, metastatic pancreatic cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Metastatic Pancreatic Cancer Market Report

  • As per DelveInsight analysis, the metastatic pancreatic cancer market is expected to grow positively at a significant CAGR during the study period (2019–2032).
  • Pancreatic cancer is typically characterized by its aggressive tumor growth and dismal prognosis. Each year more than 57,600 people in the United States (and double this number in Europe) are now diagnosed with pancreatic cancer. Of the 57,600 people with pancreatic cancer in the US, approximately half are diagnosed with metastatic pancreatic cancer.
  • Leading metastatic pancreatic cancer companies such as FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, AB Science, AstraZeneca, Eleison Pharmaceuticals, ImmunityBio, SynerGene Therapeutics, Inc., Mirati Therapeutics Inc., Incyte Corporation, AbbVie, Ability Pharmaceuticals SL, Legend Biotech USA Inc, Biomea Fusion Inc., Astellas Pharma Inc, Cue Biopharma, PureTech, and others are developing novel metastatic pancreatic cancer drugs that can be available in the metastatic pancreatic cancer market in the coming years.
  • Some key therapies for metastatic pancreatic cancer treatment include Pamrevlumab, EndoTAG-1 (ET), Fuzuloparib, Cirtuvivint, Masitinib, Ceralasertib, Glufosfamide, PD-L1 t-hank and N-803, SGT-53, MRTX849, INCMGA00012, ABBV-927, ABTL0812, LB1908, BMF-219, ASP2138, CUE-102, LYT-200, and others.

Discover which therapies are expected to grab the major metastatic pancreatic cancer market share @ Metastatic Pancreatic Cancer Market Report

Metastatic Pancreatic Cancer Overview

Pancreatic cancer is one of the most dangerous malignant tumor forms, accounting for the 4th and 5th major causes of cancer death in the United States and the European Union, respectively. Pancreatic cancer is the 9th or 10th most often diagnosed cancer in the United States (depending on gender). Based on radiological evidence, a clinical/radiographic stage classification for pancreatic cancer indicates three stages (possibly resectable, locally advanced, and metastatic). Metastatic pancreatic cancer is unresectable or cannot be removed surgically. Cancer has spread to neighboring blood arteries or lymph nodes, as well as to organs outside the pancreas.

Metastatic Pancreatic Cancer Epidemiology Segmentation

The metastatic pancreatic cancer epidemiology section provides insights into the historical and current metastatic pancreatic cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The metastatic pancreatic cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Pancreatic Cancer Incident Cases
  • Total Metastatic Pancreatic Cancer Incident Cases
  • Metastatic Pancreatic Cancer Treatable Cases

Metastatic Pancreatic Cancer Treatment Market 

The current metastatic pancreatic cancer treatment options include radiation therapy (external-beam radiation therapy, stereotactic body radiation (SBRT) or standard fraction radiation therapy), chemotherapy (Xeloda, Tarceva, Gemzar, Camptosar, Wellcovorin, Abraxane, Onivyde, Eloxatin, etc.), targeted therapy (Tarceva, Lynparza, Vitrakvi), immunotherapy, and palliative treatment. The type and stage of cancer, potential side effects, and the patient's preferences and overall health all influence treatment options and recommendations. In metastatic pancreatic cancer, gemcitabine monotherapy is the standard of care. Gemcitabine with erlotinib (Tarceva), gemcitabine with capecitabine, gemcitabine with cisplatin, and gemcitabine with nab-paclitaxel are some other drug combinations. FOLFIRINOX is a combination of 5-FU, leucovorin, oxaliplatin, and irinotecan. Gemcitabine can be used alone or in conjunction with other drugs such as (nab)-paclitaxel or capecitabine.

Oxaliplatin/fluoropyrimidine or irinotecan liposome (Onivyde) in conjunction with fluorouracil + leucovorin are the next-line medication combinations for pancreatic cancer treatment. The drug olaparib (Lynparza) has been approved for the treatment of metastatic BRCA gene mutation patients whose cancer has responded effectively to chemotherapy. 

To know more about metastatic pancreatic cancer treatment, visit @ Metastatic Pancreatic Cancer Treatment Drugs 

Key Metastatic Pancreatic Cancer Therapies and Companies

  • Pamrevlumab: FibroGen
  • EndoTAG-1 (ET): SynCore Biotechnology
  • Fuzuloparib: Jiangsu HengRui Medicine
  • Cirtuvivint: Biosplice Therapeutics
  • Masitinib: AB Science
  • Ceralasertib: AstraZeneca
  • Glufosfamide: Eleison Pharmaceuticals
  • PD-L1 t-hank and N-803: ImmunityBio
  • SGT-53: SynerGene Therapeutics, Inc.
  • MRTX849: Mirati Therapeutics Inc.
  • INCMGA00012: Incyte Corporation
  • ABBV-927: AbbVie
  • ABTL0812: Ability Pharmaceuticals SL
  • LB1908: Legend Biotech USA Inc
  • BMF-219: Biomea Fusion Inc.
  • ASP2138: Astellas Pharma Inc
  • CUE-102: Cue Biopharma
  • LYT-200: PureTech

Learn more about the FDA-approved drugs for metastatic pancreatic cancer @ Drugs for Metastatic Pancreatic Cancer Treatment 

Metastatic Pancreatic Cancer Market Dynamics

The dynamics of the metastatic pancreatic cancer market are expected to change in the coming years. Advances in computational and bioinformatics platforms, as well as a variety of other R&D practices, allow for the development of metastatic pancreatic cancer. Moreover, as the prevalence of cancer rises, so will the window of opportunity for new treatments in the metastatic pancreatic cancer market. Cancer recurrence is prevalent, even after adequate therapy; this provides a new avenue for pipeline activity in the metastatic pancreatic cancer market. Furthermore, the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate are likely to boost the growth of the metastatic pancreatic cancer market in the 7MM. 

However, several factors are impeding the growth of the metastatic pancreatic cancer market. The pipeline for metastatic pancreatic cancer is geared towards patients who have reached an advanced stage of the disease, rather than those who require first-line therapy. Moreover, the development of LAPC imposes various constraints, such as the need for a big task force, manufacturing, and purification challenges, and so on. In addition, the adverse effects of metastatic pancreatic cancer differ from patient to patient, complicating product analysis. Due to the significant research and production costs of all new items, financial constraints in the metastatic pancreatic cancer market may arise. 

Moreover, traditional cancer treatment techniques (drugs and chemotherapy) compete with cancer vaccinations which causes a dip in the growth of the metastatic pancreatic cancer market. Furthermore, the metastatic pancreatic cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the metastatic pancreatic cancer market growth. 

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

Key Metastatic Pancreatic Cancer Companies

FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, AB Science, AstraZeneca, Eleison Pharmaceuticals, ImmunityBio, SynerGene Therapeutics, Inc., Mirati Therapeutics Inc., Incyte Corporation, AbbVie, Ability Pharmaceuticals SL, Legend Biotech USA Inc, Biomea Fusion Inc., Astellas Pharma Inc, Cue Biopharma, PureTech, and others

Key Metastatic Pancreatic Cancer Therapies

Pamrevlumab, EndoTAG-1 (ET), Fuzuloparib, Cirtuvivint, Masitinib, Ceralasertib, Glufosfamide, PD-L1 t-hank and N-803, SGT-53, MRTX849, INCMGA00012, ABBV-927, ABTL0812, LB1908, BMF-219, ASP2138, CUE-102, LYT-200, and others

Scope of the Metastatic Pancreatic Cancer Market Report

  • Therapeutic Assessment: Metastatic Pancreatic Cancer current marketed and emerging therapies
  • Metastatic Pancreatic Cancer Market Dynamics: Attribute Analysis of Emerging Metastatic Pancreatic Cancer Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's Views, Analyst's Views, Metastatic Pancreatic Cancer Market Access and Reimbursement

Discover more about metastatic pancreatic cancer drugs in development @ Metastatic Pancreatic Cancer Clinical Trials

Table of Contents

1.

Metastatic Pancreatic Cancer Market Key Insights

2.

Metastatic Pancreatic Cancer Market Report Introduction

3.

Metastatic Pancreatic Cancer Market Overview at a Glance

4.

Metastatic Pancreatic Cancer Market Executive Summary

5.

Disease Background and Overview

6.

Metastatic Pancreatic Cancer Treatment and Management

7.

Metastatic Pancreatic Cancer Epidemiology and Patient Population

8.

Patient Journey

9.

Metastatic Pancreatic Cancer Marketed Drugs

10.

Metastatic Pancreatic Cancer Emerging Drugs

11.

Seven Major Metastatic Pancreatic Cancer Market Analysis

12.

Metastatic Pancreatic Cancer Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Unmet Needs

16.

SWOT Analysis

17.

Appendix

18.

DelveInsight Capabilities

19.

Disclaimer

20.

About DelveInsight

Related Reports

Metastatic Pancreatic Cancer Pipeline

Metastatic Pancreatic Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic pancreatic cancer companies, including Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, among others.

Pancreatic Cancer Market

Pancreatic Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key pancreatic cancer companies, including FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, among others.

Advanced Pancreatic Cancer Market

Advanced Pancreatic Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key advanced pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur 
info@delveinsight.com
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.